MediWound MDWD 深 滬
已收盤 09-05 16:00:00 美东时间
16.29
-0.470
-2.80%
華盛通- 最 高17.06
- 今 開16.77
- 成交量 7.61万股
- 最 低 16.25
- 昨 收 16.76
- 總市值 1.76亿
- 52周最高 22.505
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 14.14
- 委 比 -23.08%
- 總股本 1080.77万
- 歷史最高 135.17
- 量 比 0.55
- 振 幅 4.83%
- 歷史最低 7.10
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
<p>MediWound’s NexoBrid® will be showcased in 36 scientific presentations at the 21st European Burns Association Congress in Berlin, highlighting its role in advancing burn care. Data presented will demonstrate NexoBrid’s benefits for pediatric, elderly, and critically burned patients, including improved survival, recovery, and scar outcomes, as well as infection control and modulation of systemic inflammatory responses. Comparative and long-term...
09-02 11:30
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediWound Ltd. (Nasdaq: MDWD) announced that its CEO, Ofer Gonen, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The event will be available live via webcast. MediWound, a leader in enzymatic therapies for tissue repair, markets NexoBrid® for eschar removal in burns and is developing EscharEx® for chronic wounds.
08-20 11:30
MediWound Executives Purchase Shares, Signaling Confidence
An announcement from Mediwound ( ($MDWD) ) is now available. On August 18, 2025...
08-19 19:27
MediWound Q2 EPS $(1.23) Misses $(0.57) Estimate, Sales $5.708M Beat $5.677M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.57) by 115.03 percent. This is a 80.88 percent decrease over losses of $(0.68) per share from the
08-14 19:02
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
<p>MediWound Ltd. announced the publication of new Phase II data for EscharEx® in the journal <em>Advances in Wound Care</em>. The study, involving 119 patients with chronic venous leg ulcers (VLUs), demonstrated a strong correlation between wound bed preparation (WBP) and wound closure. Key findings include that wounds achieving WBP were 4.1 times more likely to close compared to those that did not, and early WBP within 14 days significantly inc...
08-13 12:45
MediWound to Report Second Quarter 2025 Financial Results
<p>MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, announced the release of its second quarter 2025 financial results on August 4, 2025. The company will host a conference call and live webcast on Thursday, August 14, 2025, at 8:30 a.m. Eastern Time to discuss the results and provide updates. The call can be accessed via toll-free, Israel, or international numbers. An archived webcast wi...
08-04 11:30
美股大行评级 | 高盛上调微软目标价从480美元至550美元，Snowflake获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132593314765758464.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持IDEAYA Biosciences(IDYA)"超配"评级，目标价从63美元升至66美元</p> <p>• Needham：上调Inogen(INGN)评级至"买入"，目标价12美元</p> <p>• E
05-23 11:19
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $31
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and raises the price target from $25 to $31.
05-22 19:09
电话会总结 ｜ MediWound (MDWD)2025年Q1业绩电话会核心要点
<span> <meta content="no-referrer" name="referrer"></span><span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote> <p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**： MediWound (MDWD) 在2025年第一季度的总营收为400万美元，相较于2024年第一季度的500万美元减少了100万美元，主要由于NexoBrid项目接近完成，BARDA资助的开发服务收入下降。第一季度的毛利润为70万美元，毛利率从2024年同期的12%上升至19%。研发费用为290万美元，高于2024年第一季度的150万美元，反映了对EscharEx VALUE三期试验的持续投资。销售与管理费用（S
05-22 12:05
